ONTX Onconova Therapeutics Inc.

3.28
-0.46  -12%
Previous Close 3.74
Open 3.73
Price To Book -12.62
Market Cap 19,675,159
Shares 5,998,524
Volume 25,018
Short Ratio
Av. Daily Volume 34,417

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Special Protocol Assessment (SPA) submission announced January 2, 2019.
Oral Rigosertib and azacitidine
First-line HR-MDS (high risk myelodysplastic syndromes)
Phase 3 enrolment to be completed 2H 2019. Data anticipated 2H 2019 (April 2019 guidance).
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association
  2. Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT
  3. Onconova Therapeutics Announces Presentations at Three Upcoming Conferences
  4. Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results
  5. Newtown biopharm firm could reap $50M from Chinese licensing deal
  6. Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China
  7. Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results
  8. Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark
  9. Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9
  10. Edited Transcript of ONTX earnings conference call or presentation 26-Mar-19 1:00pm GMT
  11. Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results
  12. Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes
  13. Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results
  14. Onconova Therapeutics, Inc. to Participate at the 31st Annual ROTH Conference March 17-19, 2019 in Orange County, CA
  15. Onconova Therapeutics, Inc. to Present Corporate Update at the BIO CEO & Investor Conference in New York City
  16. Advancements in the Treatment of Myelodysplastic Syndromes and RAS-Mutated Lung Cancers to be Presented by Key Opinion Leaders on Thursday, February 7, 2019, in New York City
  17. Onconova Therapeutics, Inc. to Present at the NobleCON 15th Annual Investor Conference in Fort Lauderdale, FL
  18. Bucks County biopharm firm names new CEO
  19. Onconova Therapeutics Promotes Dr. Steven M. Fruchtman to Chief Executive Officer
  20. Onconova Submits Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib in Combination with Azacitidine (Vidaza®) for First-Line Myelodysplastic Syndromes (MDS)